01—Abstract
Summary
Summary of the 8-K filed June 13, 2025. Cited figures are marked; the original filing is the authoritative source.
On June 13, 2025, Ventas, Inc. (VTR) entered into Amendment No. 1 to its ATM Sales Agreement dated September 18, 2024, with a group of sales agents and forward purchasers named in the filing.
Under the amendment, the aggregate gross sales price of common stock now available for issuance under the Sales Agreement is $2.25 billiona, excluding shares previously sold under the agreement before Amendment No. 1 was executed. Any shares offered, issued and sold under the amended agreement, including any borrowed shares that forward purchasers may sell, will be made under the company's Form S-3 registration statement (File No. 333-277185) and a prospectus supplement filed the same day. The filing includes a Davis Polk & Wardwell LLP legality opinion (Exhibit 5.1) on the shares.
The filing is primarily a procedural disclosure of an at-the-market equity program update. Its forward-looking statements flag dilution from future equity sales among the risk factors, alongside the company's broader exposure to healthcare policy, tenant and manager health, leverage and capital market conditions.
02—Key points
Key Highlights
- Ventas amended its ATM Sales Agreement (originally dated September 18, 2024) on June 13, 2025, with a broad syndicate of sales agents and forward purchasers.
- The aggregate gross sales price of common stock available for issuance under the amended agreement is $2.25 billion, excluding shares sold before the amendment.
- Shares may be sold under the company's Form S-3 (File No. 333-277185) and a prospectus supplement filed the same day.
- Forward purchasers may offer and sell borrowed common stock under the agreement, in addition to shares the company issues directly.
- Davis Polk & Wardwell LLP provided an opinion on the validity of shares that may be issued (Exhibit 5.1).
- The filing's risk disclosures specifically cite the risk of potential dilution from future sales or issuances of equity securities.
03—Questions
Frequently Asked Questions
What did Ventas change in its ATM program?
Amendment No. 1 to the ATM Sales Agreement, dated June 13, 2025, sets the aggregate gross sales price of common stock available for issuance at $2.25 billion, excluding shares sold before the amendment.
How will the shares be registered and sold?
Shares will be offered and sold under the company's Form S-3 registration statement (File No. 333-277185) and a prospectus supplement filed on June 13, 2025.
Who are the parties to the agreement?
The filing names a group of sales agents, including BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, Morgan Stanley and UBS Securities, among others, acting as sales agents and/or forward sellers, and a corresponding group of banks acting as forward purchasers.
Does this filing mean shares are being issued now?
The filing does not state that any shares have been sold under the amendment. It establishes the capacity available for future offerings and sales under the agreement.
What dilution risk should investors consider?
The forward-looking statements list the potential for dilution from future sales or issuances of the company's equity securities as a risk factor.
04—Continue